MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

被引：0
|
作者：
Staehler, Michael D.
Bergmann, Lothar
Gruenwald, Viktor
Huschke, Torsten
Keilholz, Ulrich
Ohlmann, Carsten Henning
Stoeckle, Michael
Weigang-Koehler, Karin
Hauswald, Kirsten
Schaller, Felix
Strassl, Luise
Junker, Kerstin
机构：
[1] Univ Hosp Grosshadern, Munich, Germany
[2] Dept Med, Frankfurt, Germany
[3] Univ Canc Ctr Frankfurt, Frankfurt, Germany
[4] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[5] Univ Hosp Jena, Jena, Germany
[6] Charite, Dept Hematol & Med Oncol, CBF, Berlin, Germany
[7] Univ Saarland, Homburg, Germany
[8] Hosp Nurnberg, Nurnberg, Germany
[9] IOMEDICO AG, Freiburg, Germany
[10] Univ Hosp Jena, Dept Urol, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.467
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
467
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC)
    Khorasanchi, Adam
    Kwok, Christopher
    Psutka, Sarah P.
    Hinkley, Megan
    Dason, Shawn
    Yang, Yuanquan
    Verschraegen, Claire F.
    Gross, Evan
    Orcutt, Delaney
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT
    Rha, Sun Young
    Lee, Se-Hoon
    Ou, Yen-Chuan
    Ahn, Jin-Hee
    Chang, Yen-Hwa
    Srimuninnimit, Vichien
    Lim, Ho Yeong
    Chung, Ik-Joo
    Pang, See-Tong
    Xue, Hong-Ling
    Panneerselvam, Ashok
    Chung, Jooseop
    Toh, Chee-Keong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] AN INTERNATIONAL EXPANDED ACCESS PROGRAM (EAP) OF EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO ARE INTOLERANT OF OR HAVE PROGRESSED AFTER PRIOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY
    Grunwald, V.
    Miller, K.
    Machiels, J.
    Lee, S.
    Larkin, J.
    Yuan, R.
    Rosamilia, M.
    Booth, J.
    Karakiewicz, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 274 - 274
  • [24] Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP)
    Grunwald, V.
    Bodrogi, I.
    Miller, K.
    Machiels, J. H.
    Lee, S.
    Chowdhury, S.
    Yuan, R.
    Rosamilia, M.
    Booth, J. L.
    Karakiewicz, P. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
    Meric-Bernstam, Funda
    Tannir, Nizar M.
    Iliopoulos, Othon
    Lee, Richard J.
    Telli, Melinda L.
    Fan, Alice C.
    DeMichele, Angela
    Haas, Naomi B.
    Patel, Manish R.
    Harding, James J.
    Voss, Martin H.
    Owonikoko, Taofeek K.
    Carthon, Bradley
    Srinivasan, Ramaprasad
    Bendell, Johanna C.
    Jenkins, Yonchu
    Whiting, Sam H.
    Orford, Keith
    Bennett, Mark K.
    Bauer, Todd M.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1540 - 1548
  • [26] Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
    Yorio, Jeffrey Thomas
    Asnis-Alibozek, Aviva G.
    Kasturi, Vijay
    Hutson, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
    Escudier, B.
    Bracarda, S.
    Maroto, J. P.
    Szczylik, C.
    Nathan, P.
    Negrier, S.
    Castellano, D.
    Weiss, C.
    Porta, C.
    Gruenwald, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S643 - S643
  • [28] The SUNPAZ study: Results of an open label, single arm trial to evaluate patients with mRCC treated with everolimus after failure of first line therapy with sunitinib or pazopanib.
    Schostak, Martin
    Nusch, Arnd
    de Geeter, Patrick
    Decker, Thomas
    Resch, Anna
    Weiss, Claudia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [29] Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response
    Koo, Dong Hoe
    Park, Inkeun
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Lee, Dae Ho
    You, Dalsan
    Jeong, In Gab
    Song, Cheryn
    Hong, Bum-Sik
    Hong, Jun Hyuck
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment
    Mancuso, A. P.
    De Paola, E. Donato
    Catalano, A.
    Calabro, F.
    Messina, C.
    Zivi, A.
    Cerbone, L.
    Vigna, L.
    Caristo, R.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345